Literature DB >> 26510507

Can radical prostatectomy shortly after prostate biopsy affect intra-operative and postoperative outcomes?

Lucio Dell'Atti1, Gaetano Capparelli, Stefano Papa, Carmelo Ippolito.   

Abstract

Entities:  

Mesh:

Year:  2016        PMID: 26510507      PMCID: PMC4854114          DOI: 10.4103/1008-682X.165949

Source DB:  PubMed          Journal:  Asian J Androl        ISSN: 1008-682X            Impact factor:   3.285


× No keyword cloud information.
Dear Editor, We retrospectively evaluated the patients who underwent radical prostatectomy (RP) for prostate cancer (PCa) if the interval between PB and RP had any impact on immediate outcomes after surgery treatment. The study population comprised 473 patients with localized or locally advanced PCa (clinical stage T1c to T3c) diagnosed via a transrectal ultrasound-guided prostate biopsy (TPB) conducted by three urologists. The patients who underwent RP (109 with laparoscopic technique and 364 with open technique) from March 2007 to April 2013 at our Department of Urology were reviewed. All RP procedures were performed by three experienced surgeons. TPB was performed with the patient in the left lateral decubitus using a General Electric Logiq 7 machine (GE Healthcare, Milwaukee, WI, USA) equipped with a 5–9 MHz multi-frequency convex probe “end-fire.” After having image the prostate, sampling was carried out with an 18-gauge Tru-Cut (Bard Biopsy Systems, Tempe, AZ, USA) needle powered by an automatic spring-loaded biopsy disposable gun. The patients were divided into three groups according to the time interval between biopsy and RP, Group 1 (G1): ≤4 weeks, Group 2 (G2): >4 weeks and ≤6 weeks, and Group 3 (G3): >6 weeks. We excluded patients who received neoadjuvant androgen ablation therapy and/or radiotherapy before RP, diagnosis at the time of surgery for benign prostatic hyperplasia such as transurethral resection of the prostate, and fewer than six biopsy cores at diagnosis. Demographic and clinicopathologic variables (patient's age, body mass index [BMI], prostate-specific antigen [PSA] level at the time of diagnosis, prostate volume [PV], and biopsy Gleason score) were recorded and compared these variables between three groups. Using a series of univariate and multivariate logistic regression analysis, it was evaluated whether the interval between biopsy and RP was a significant independent predictor of operative duration (OD), estimated blood loss (EBL), positive surgical margin (PSM), hospital stay (HS), and urinary continence (UC) after RP. Multivariate logistic and linear regression models were performed to examine the effect of the interval between biopsy and RP on OD, EBL, PSM, HS, and UC. Demographic and clinicopathologic variables were analyzed using a Fisher's exact test and Chi-square analysis to determine statistical differences between the three groups. All statistical analyses were conducted on Microsoft Excel 2010 platform version 10.1. P <0.05 was considered statistically significant. A total of 116 patients (24.5%) were in G1, 179 (37.9%) in G2, and 178 (37.6%) in G3. The mean ± standard deviation age of enrolled patients was 63.2 ± 6.8 years, with a PV of 34.4 ± 11.7 ml, initial PSA of 10.8 ± 9.7 ng ml−1, and BMI of 27.8 ± 4.3 kg m−2. The number of biopsy cores was 10.4 ± 3.0. No significant difference was noted between the three groups when comparing age, preoperative PSA level, prostate volume, BMI, biopsy number, clinical stage, and Gleason grade. On univariate analysis, the mean OD time (223.4 ± 78.5 min) was longer (P < 0.002) and EBL (652.11 ± 321.07 ml) was greater (P < 0.001) in G2 (). The mean core number <10 (n: 68) was 7.6 (range: 7–9) and the mean core number >10 (n: 405) was 13.8 (range: 10–24). In cases of extended biopsy (more than 10 cores obtained), operative time was longer (232.4 min vs 214.9 min), but no clinical significance was showed on multivariate analysis. An increasing EBL was associated with an elevated BMI in all groups (P < 0.001). Longer OD times were associated with an elevated BMI (P < 0.001) and Gleason grade (P = 0.003). Also, positive surgical margins were associated with pathologic stage (P = 0.006), PSA level (P < 0.002), Gleason grade (P = 0.003), and extracapsular extension (P < 0.002). Finally, urinary continence was associated with patient age (P = 0.001). Both univariate and multivariate analyses, however, failed to show that the interval from biopsy to surgery had any significant relations with PSM, HS, and postoperative urinary continence. There were no statistically significant differences in terms of complication rate between three groups (P = 0.325). Fifty patients (10.5%) developed complications, including pelvic hematoma in 4.9% (23/473), transfer to intensive care for cardiac and respiratory monitoring in 2.3% (11/473), and lymphocele formation in 3.4% (16/473). No patient died.
Table 1

Demographic, clinicopathologic features and perioperative outcomes of patients undergoing radical prostatectomy

Demographic, clinicopathologic features and perioperative outcomes of patients undergoing radical prostatectomy Prostate cancer is a major cause of morbidity among men worldwide. It is generally considered a relatively slow-growing malignancy.1 The delay for pretreatment diagnostics or psychological reasons between diagnosis and active therapy of PCa is often common.2 The prostate biopsy is the most common used procedure to detect PCa. During the last decade, the number of needle biopsy cores taken has increased, as have biopsies in younger patients and repeated biopsies.3 Traditionally, urologists recommend an interval of >4–6 weeks after transrectal prostate biopsy before RP, to allow time for resolution of biopsy-induced inflammation that might eliminate the surgical planes of dissection.45 In the study of Ikonen et al.,6 assessing endorectal magnetic resonance imaging after prostate biopsy, 77% of the patients had visible hemorrhage after biopsy. The effects diminish after 21 days, with an obvious decrease in the amount of blood by 28 days. A fair number of studies have been carried out on surgical outcomes compared according to the interval from prostate biopsy to surgery.789 Lee et al.5 showed, on a series of 169 patients, no significant correlation in perioperative outcomes and complications with the interval after biopsy. However, they noted a statistically significant association between prostate biopsy and RP in terms of intraoperative blood loss. Eggener et al.4 reported that a shorter interval between prostate biopsy and RP did not adversely affect surgical outcome. Similar to these studies, our data suggest that the interval from biopsy to surgery had no significant correlations with OD, EBL, PSM, and urinary continence (P = 0.527). Similarly, extension of biopsy core number to 14 cores did not influence the short-term result of RP. However, in this study, long-term postoperative outcomes such as the rates of biochemical recurrence and overall survival were excluded. In this respect, further studies are recommended with a prospective experimental design and in a larger subject group, particularly in terms of functional and biological recurrence.

AUTHOR CONTRIBUTIONS

LD carried out the preliminary analysis, drafted the manuscript. GC performed statistics analysis. SP participated in its design and coordination, and CI was the main surgeon of this study, participated in patients enrolls. All authors read and approved the final manuscript.

COMPETING INTERESTS

All authors declared no competing interests.
  9 in total

1.  Total prostatectomy within 6 weeks of a prostate biopsy: is it safe?

Authors:  Kishore T Adiyat; Manoharan Murugesan; Devendar Katkoori; Ahmed Eldefrawy; Mark S Soloway
Journal:  Int Braz J Urol       Date:  2010 Mar-Apr       Impact factor: 1.541

2.  Radical prostatectomy shortly after prostate biopsy does not affect operative difficulty or efficacy.

Authors:  Scott E Eggener; Ofer Yossepowitch; Angel M Serio; Andrew J Vickers; Peter T Scardino; James A Eastham
Journal:  Urology       Date:  2007-06       Impact factor: 2.649

3.  Biopsy related prostate status does not affect on the clinicopathological outcome of robotic assisted laparoscopic radical prostatectomy.

Authors:  Hoon Choi; Young Hwii Ko; Sung Gu Kang; Seok Ho Kang; Hong Seok Park; Jun Cheon; Vipul R Patel
Journal:  Cancer Res Treat       Date:  2009-12-31       Impact factor: 4.679

4.  Correlation between prolonged use of aspirin and prognostic risk in prostate cancer.

Authors:  Lucio Dell'Atti
Journal:  Tumori       Date:  2014 Sep-Oct       Impact factor: 2.098

5.  Does the interval between prostate biopsy and radical prostatectomy affect the immediate postoperative outcome?

Authors:  Daniel K Lee; Veerasuthpursh Allareddy; Michael A O'donnell; Richard D Williams; Badrinath R Konety
Journal:  BJU Int       Date:  2006-01       Impact factor: 5.588

Review 6.  Timing of curative treatment for prostate cancer: a systematic review.

Authors:  Roderick C N van den Bergh; Peter C Albertsen; Chris H Bangma; Stephen J Freedland; Markus Graefen; Andrew Vickers; Henk G van der Poel
Journal:  Eur Urol       Date:  2013-02-22       Impact factor: 20.096

7.  Interval from prostate biopsy to robot-assisted radical prostatectomy: effects on perioperative outcomes.

Authors:  George L Martin; Rafael N Nunez; Mitchell D Humphreys; Aaron D Martin; Robert G Ferrigni; Paul E Andrews; Erik P Castle
Journal:  BJU Int       Date:  2009-06-22       Impact factor: 5.588

8.  Optimal timing of post-biopsy MR imaging of the prostate.

Authors:  S Ikonen; L Kivisaari; T Vehmas; P Tervahartiala; J O Salo; K Taari; S Rannikko
Journal:  Acta Radiol       Date:  2001-01       Impact factor: 1.701

9.  The optimal timing of post-prostate biopsy magnetic resonance imaging to guide nerve-sparing surgery.

Authors:  Young Hwii Ko; Phil Hyun Song; Ki Hak Moon; Hee Chang Jung; Jun Cheon; Deuk Jae Sung
Journal:  Asian J Androl       Date:  2014 Mar-Apr       Impact factor: 3.285

  9 in total
  1 in total

1.  Does time interval between prostate biopsy and surgery affect outcomes of radical prostatectomy? A systematic review and meta-analysis.

Authors:  Jie Li; Qing Jiang; Qiubo Li; Yuanfeng Zhang; Liang Gao
Journal:  Int Urol Nephrol       Date:  2019-11-30       Impact factor: 2.370

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.